Given that susceptibility to infections is one of the primary causes of morbidity and mortality in lupus patients, we evaluated splenic leukocytes to assess their ability to respond to viral and bacterial infections by using TLR7 and TLR9 agonists in vivo as a model of sterile inflammation. This evidence concerns the gene TLR9 and systemic lupus erythematosus.